Table of Contents Author Guidelines Submit a Manuscript
Volume 6, Issue 3, Pages 83-87

A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST)

1Royal Marsden Hospital, London, UK
2St James's Hospital, Leeds, UK
3Middlesex Hospital, London, UK
4Christie Hospital, Manchester, UK
5Newcastle General Hospital, Newcastle, UK
6Royal Orthopaedic Hospital, Birmingham, UK
7Weston Park Hospital, Sheffield, UK
8FRCP, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Gastrointestinal stromal tumour (GIST) is the commonest mesenchymal tumour to affect the gastrointestinal tract. Appropriate management requires accurate diagnosis and the skills of a multidisciplinary team. Surgery is the only curative treatment option and should be performed whenever feasible, by experienced personnel. For patients with advanced unresectable or metastatic disease, the receptor tyrosine kinase inhibitor imatinib offers effective therapy and can provide effective palliation for the majority of patients with this disease. The background to this recent development and a guideline for the management of GIST is proposed.